IP Library Granted Patent US 12,390,444
Granted Patent B2
US 12,390,444 · App. 17/965,633 · Granted Aug 19, 2025

Stabilizing vitamin C topical formulations

Inventor: Jihoon P. Baek (Los Angeles, CA)
Assignee: MF Beauty Partners LLC
A61K31/375A61K8/345A61K8/365A61K8/676A61K9/0014A61K31/17A61K31/19
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,390,444
App. No.
17/965,633
Granted
Aug 19, 2025
Kind
B2
Abstract

Topical formulations of L-ascorbic acid dissolved in a combination of a urea agent and a non-aqueous skin-compatible solvent are provided. The formulations are storage stable for an extended period of time without significant degradation of the L-ascorbic acid in the composition, are have desirable physical properties. The topical formulations can include high concentrations of the L-ascorbic acid. The topical formulations can include cinnamic acid or derivatives thereof as a penetration enhancer and stabilizing component of ascorbic acid. Topical compositions of this disclosure find use in treating or preventing a variety of cosmetic and/or dermatological conditions as well as to reduce the appearance of chronological and/or environmentally-caused skin aging.

Claims (59)

1. A storage stable topical composition comprising:

a. 16% to 20% by weight ascorbic acid;

b. 5 to 10% by weight of a solubility and penetrating agent that is a urea agent;

c. 0.1% to 1% by weight of ferulic acid; and

d. less than 10% by weight in total of one or more optional additional components;

e. dissolved in a non-aqueous skin-compatible solvent comprising 1,3-propanediol; wherein the ascorbic acid is dissolved at a concentration (AA) that is above its maximum concentration in the solvent alone (X), and the urea agent is dissolved at a concentration that is (AA−X)*1.25;

wherein the composition is substantially free of water, and wherein the composition does not comprise niacinamide.

2. The composition of claim 1 , wherein the composition demonstrates less than 10 mol % degradation of the ascorbic acid after storage for 6 weeks at 40° C.±2° C. in a sealed container.

3. The composition of claim 1 , wherein the urea agent is urea, hydroxyethyl urea, or a mixture of urea and hydroxyethyl urea.

4. The composition of claim 1 , wherein the solvent further comprises 1,2 propanediol, 1,3 butanediol, 1,5 pentanediol, 1,2 hexanediol, 1,6 hexanediol, 1,2 hexanediol, glycerol, diglycerol, ethoxydiglycol, dimethyl isosorbide, or any combination thereof.

5. The composition of claim 4 , wherein the solvent further comprises 1,2 hexanediol.

6. The composition of claim 1 , wherein the one or more optional additional components are selected from tocopherols, tocotrienols, azelaic acid, hydroxy acids, panthenol, Pinus pinaster bark extract, emulsifying agent, hyaluronic acid complex, madecassoside, acetyl zingerone, bakuchiol, and bis-ethylhexylhydroxydimethoxybenzylmalonate.

7. The composition of claim 6 , wherein the composition comprises:

20% by weight ascorbic acid;

10% by weight urea agent;

0.5% by weight ferulic acid;

69% by weight 1,3-propanediol; and

0.5% by weight in total of diglycerin and Pinus pinaster bark extract.

8. The composition of claim 6 , wherein the composition comprises:

20% by weight ascorbic acid;

10% by weight urea agent; and

0.5% by weight ferulic acid; and

the solvent consists of 1,3-propanediol.

9. The composition of claim 6 , wherein the composition consists of:

20% by weight ascorbic acid;

10% by weight urea agent;

0.5% by weight ferulic acid;

69% by weight 1,3-propanediol; and

0.5% by weight in total of diglycerin and Pinus pinaster bark extract;

wherein the composition is substantially free of water, and wherein the composition does not consist of niacinamide.

10. The composition of claim 1 , wherein the composition comprises 20% by weight of ascorbic acid.

11. The composition of claim 1 , wherein the ratio by weight of ascorbic acid to urea agent is 2 to 1.

12. The composition of claim 1 , wherein the composition comprises at least 60% by weight of the solvent comprising 1,3-propanediol.

13. The composition of claim 1 , wherein the composition comprises 10% by weight urea.

14. The composition of claim 1 , wherein the composition comprises 0.5% by weight of diglycerin and Pinus pinaster bark extract.

15. The composition of claim 1 , wherein the ratio by weight of ascorbic acid to urea agent is between 3 and 3.5.

16. The composition of claim 1 , wherein the optional additional component comprises azelaic acid.

17. The composition of claim 16 , wherein the composition comprises 3% to 10% by weight of the azelaic acid.

18. The composition of claim 1 , wherein the one or more optional additional components comprises 2% or less by weight of Pinus pinaster bark extract.

19. The composition of claim 1 , wherein the optional additional component is hydroxy acid is selected from glycolic acid, lactic acid, mandelic acid, salicylic acid, capryloyl salicylic acid, salicyloyl phytosphingosine, gluconolactone, lactobionic acid, maltobionic acid, and combinations thereof.

20. An emulsion composition, comprising:

the composition of claim 1 ;

an oil component; and

an optional emulsifying agent.

21. The composition of claim 1 , wherein the composition does not comprise vitamin E acetate.

22. The composition of claim 1 , wherein the composition does not consist of niacinamide.

23. A storage stable topical composition comprising:

20% by weight ascorbic acid;

urea, wherein the ratio by weight of ascorbic acid to urea is 1.8 to 2.2;

0.1% to 1% by weight of ferulic acid; and

less than 1% by weight in total of Pinus pinaster bark extract;

dissolved in a non-aqueous solvent comprising 60% to 75% by weight of 1,3-propanediol;

wherein the composition is substantially free of water, and wherein the composition does not comprise niacinamide.

24. The composition of claim 23 , wherein the composition consists essentially of:

20% by weight ascorbic acid;

10% by weight urea;

0.5% by weight ferulic acid;

less than 1% by weight in total of Pinus pinaster bark extract; and

1,3-propanediol.

Assignments (4)
ASSET PURCHASE AGREEMENT Recorded Apr 11, 2025
From: ICB (AN ABC), LLC
To: MF BEAUTY PARTNERS LLC
Reel/Frame 070820/0964 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 9, 2025
From: BAEK CLINICAL INC.
To: ICB (AN ABC), LLC
Reel/Frame 070781/0445 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 8, 2025
From: BAEK, JIHOON P.
To: BAEK CLINICAL INC.
Reel/Frame 070764/0250 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 13, 2022
From: BAEK, JIHOON P.
To: BAEK CLINICAL INC.
Reel/Frame 061418/0634 →
Continuity (3)
Continuation PCTUS2021027830 · Apr 16, 2021
Provisional Application 63010878 · Apr 16, 2020
Related Publication 20230057927A1 · Feb 23, 2023
References Cited (114)
US 2539483A · Ruskin · 1951 [cited by applicant]
US 4960764A · Figueroa et al. · 1990 [cited by applicant]
US 4983382A · Wilmott et al. · 1991 [cited by applicant]
US 5140043A · Darr et al. · 1992 [cited by applicant]
US 5308621A · Taylor et al. · 1994 [cited by applicant]
US 5670139A · Allard et al. · 1997 [cited by applicant]
US 5736567A · Cantin et al. · 1998 [cited by applicant]
US 5801192A · Dumas et al. · 1998 [cited by applicant]
US 5925679A · Mather et al. · 1999 [cited by applicant]
US 6013255A · Edens et al. · 2000 [cited by applicant]
US 6020367A · Duffy et al. · 2000 [cited by applicant]
US 6146664A · Siddiqui · 2000 [cited by applicant]
US 6361783B2 · Moaddel et al. · 2002 [cited by applicant]
US 6462025B2 · Vishnupad · 2002 [cited by applicant]
US 7108860B2 · Dueva et al. · 2006 [cited by applicant]
US 7179841B2 · Zielinski et al. · 2007 [cited by applicant]
US 8313756B1 · Landau et al. · 2012 [cited by applicant]
US 8344024B2 · Czarnota et al. · 2013 [cited by applicant]
US 9018177B2 · Lauten et al. · 2015 [cited by applicant]
US 9132080B2 · Zecchino et al. · 2015 [cited by applicant]
US 9248082B2 · Pinnell et al. · 2016 [cited by applicant]
US 9901533B2 · Zecchino et al. · 2018 [cited by applicant]
US 10149808B2 · Pan et al. · 2018 [cited by applicant]
US 10435536B2 · Swanzy · 2019 [cited by applicant]
US 10532017B2 · Lema et al. · 2020 [cited by applicant]
US 20010007653A1 · Moaddel et al. · 2001 [cited by applicant]
US 20040033963A1 · Yu et al. · 2004 [cited by applicant]
US 20040067890A1 · Gupta · 2004 [cited by applicant]
US 20040219122A1 · Masuda et al. · 2004 [cited by applicant]
US 20050008592A1 · Gardel et al. · 2005 [cited by applicant]
US 20050154054A1 · Zielinski et al. · 2005 [cited by applicant]
US 20070003536A1 · Zimmerman et al. · 2007 [cited by applicant]
US 20070077261A1 · Zhang · 2007 [cited by applicant]
US 20070172436A1 · Zhang · 2007 [cited by applicant]
US 20080057014A1 · Masuda et al. · 2008 [cited by applicant]
US 20080175919A1 · Mohammadi et al. · 2008 [cited by applicant]
US 20080274068A1 · Tanaka et al. · 2008 [cited by applicant]
US 20090312724A1 · Pipkin et al. · 2009 [cited by applicant]
US 20100189761A1 · Friedman et al. · 2010 [cited by applicant]
US 20130131162A1 · Kaplan · 2013 [cited by applicant]
US 20140142175A1 · Kelada et al. · 2014 [cited by applicant]
US 20140147525A1 · de Paula et al. · 2014 [cited by applicant]
US 20150250709A1 · Gan · 2015 [cited by examiner]
US 20160101029A1 · Sanmiguel · 2016 [cited by applicant]
US 20160256369A1 · Dutton et al. · 2016 [cited by applicant]
US 20160354328A1 · Huang et al. · 2016 [cited by applicant]
US 20170224760A1 · Garruto et al. · 2017 [cited by applicant]
US 20180071190A1 · Albrecht et al. · 2018 [cited by applicant]
US 20180071203A1 · Gan et al. · 2018 [cited by applicant]
US 20180116927A1 · Chaudhuri · 2018 [cited by applicant]
US 20180228714A1 · Thomas · 2018 [cited by applicant]
US 20180280286A1 · Elsen-Wahrer et al. · 2018 [cited by applicant]
US 20190038689A1 · Kalahasti et al. · 2019 [cited by applicant]
US 20190151214A1 · Shaffer et al. · 2019 [cited by applicant]
US 20190192393A1 · Chen et al. · 2019 [cited by applicant]
US 20190290639A1 · Jackson · 2019 [cited by applicant]
US 20190336421A1 · Maruyama · 2019 [cited by applicant]
US 20200121627A1 · Park · 2020 [cited by examiner]
US 20210228467A1 · Baek · 2021 [cited by applicant]
CN 1192134A · 1998 [cited by applicant]
CN 101282708A · 2008 [cited by applicant]
CN 109475472A · 2009 [cited by applicant]
CN 106580798B · 2019 [cited by applicant]
CN 110368326 · 2019 [cited by examiner]
EP 1742710B1 · 2009 [cited by applicant]
JP H05229927A · 1993 [cited by applicant]
JP H10509735A · 1998 [cited by applicant]
JP 2008088188A · 2008 [cited by applicant]
JP 2013170124A · 2013 [cited by applicant]
JP 2017509705A · 2017 [cited by applicant]
WO WO9319743A1 · 1993 [cited by applicant]
WO WO9639119A1 · 1996 [cited by applicant]
WO WO199933439A1 · 1999 [cited by applicant]
WO WO2005070380A1 · 2005 [cited by applicant]
WO WO2007040027A1 · 2007 [cited by applicant]
WO WO2008030308A1 · 2008 [cited by applicant]
WO WO2012053009A2 · 2012 [cited by applicant]
WO WO2014184173A1 · 2014 [cited by applicant]
WO WO2015143399A1 · 2015 [cited by applicant]
WO WO2016141315A1 · 2016 [cited by applicant]
WO WO2018081779A1 · 2018 [cited by applicant]
WO WO2020081868A1 · 2020 [cited by applicant]
WO WO2020086820A1 · 2020 [cited by applicant]
WO WO2021212077A3 · 2022 [cited by applicant]
Hu et al., CN 110368326, published: Oct. 2019, English machine translation obtained May 6, 2023. (Year: 2023). [cited by examiner]
Belcher, L. A. et al. “Evaluating 1,3-Propanediol for Potential Skin Effects.” Cosmetics & Toiletries, vol. 125, No. 5, May 2010, pp. 1-4. [cited by applicant]
Choi, Y.K. et al., “Effects of vitamin C vs. multivitamin on melanogenesis: comparative study in vitro and in vivo,” International journal of Dermatology, vol. 49, Iss. 2, Feb. 2010, pp. 218-226. [cited by applicant]
Espinal-Perez, L.E. et al., “A double-blind randomized trial of 5% ascorbic acid vs. 4% hydroquinone in melasma,” International Journal of Dermatology 43(8), Aug. 2004, pp. 604-607. [cited by applicant]
European Patent Office, Extended European Search Report, European Patent Application No. 19874453.4, Jun. 27, 2022, nine pages. [cited by applicant]
Kameyama, K. et al., “Inhibitory effect of magnesium l-ascorbyl-2-phosphate (VC-PMG) on melanogenesis in vitro and in vivo,” Journal of the American Academy of Dermatology, vol. 34, Iss. 1, Jan. 1996, pp. 29-33. [cited by applicant]
Kim, S. et al., “Stabilization of L-ascorbic acid in cosmetic emulsions,” Journal of Industrial and Engineering Chemistry, vol. 57, Jan. 25, 2018, pp. 193-198. [cited by applicant]
Maia, A.M. et al., “Validation of HPLC stability-indicating method for Vitamin C in semisolid pharmaceutical/cosmetic preparations with glutathione and sodium metabisulfite, as antioxidants,” Talanta, vol. 71, Jun. 12, … [cited by applicant]
PCT International Search Report and Written Opinion, PCT Application No. PCT/US2022/047305, Jan. 24, 2023, 18 pages. [cited by applicant]
PCT International Search Report and Written Opinion, PCT Application No. PCT/US2022/077119, Jan. 18, 2023, 19 pages. [cited by applicant]
PCT International Search Report and Written Opinion, PCT Application No. PCT/US2021/027835, Aug. 11, 2021, 17 pages. [cited by applicant]
PCT International Search Report and Written Opinion, PCT Application No. PCT/US2021/027834, Aug. 12, 2021, 14 pages. [cited by applicant]
PCT International Search Report and Written Opinion, PCT Application No. PCT/US2021/027832, May 11, 2022, 18 pages. [cited by applicant]
PCT International Search Report and Written Opinion, PCT Application No. PCT/US2021/027831, Aug. 11, 2021, 16 pages. [cited by applicant]
PCT International Search Report and Written Opinion, PCT Application No. PCT/US2021/027830, Aug. 11, 2021, 17 pages. [cited by applicant]
PCT International Preliminary Report on Patentability, PCT Application No. PCT/US2021/027830, Oct. 27, 2022, ten pages. [cited by applicant]
PCT International Search Report and Written Opinion, PCT Application No. PCT/US2021/027827, Jul. 16, 2021, 13 pages. [cited by applicant]
PCT International Preliminary Report on Patentability, PCT Application No. PCT/US2021/027827, Oct. 27, 2022, seven pages. [cited by applicant]
PCT International Search Report and Written Opinion, PCT/US2019/056822, dated Dec. 27, 2019, 16 pages. [cited by applicant]
Sarkar, R. et al., “Cosmeceuticals for Hyperpigmentation: What is Available?,” Journal of Cutaneous and Aesthetic Surgery, vol. 6, No. 1, Jan. 2013, pp. 4-11. [cited by applicant]
Wikipedia, “Ferulic acid,” Jan. 24, 2020, seven pages, [Online] Retrieved from the Internet <URL: https://en.wikipedia.org/w/index.php?title=Ferulic_acid&oldid=937396103>. [cited by applicant]
Ferreira, A.S. et al., “In Vivo Xylitol Primary Dermal Irritation and Phototoxicity Evaluation,” Latin American Journal of Pharmacy, vol. 28, No. 2, Mar. 2009, pp. 192-195. [cited by applicant]
United States Office Action, U.S. Appl. No. 17/965,628, Apr. 19, 2023, 11 pages. [cited by applicant]
United States Office Action, U.S. Appl. No. 17/286,434, May 4, 2023, 17 pages. [cited by applicant]
European Patent Office, Extended European Search Report, European Patent Application No. 21788324.8, Aug. 6, 2024, 19 pages. [cited by applicant]
European Patent Office, Partial Supplementary European Search Report with Provisional Opinion, European Patent Application No. 21788324.8, May 16, 2024, 23 pages. [cited by applicant]
Glambrat. “Revolution: Good Vibes Lip Balm.” INCIDecoder, Dec. 29, 2019, 5 pages, [Online] [Retrieved Apr. 7, 2025], Retrieved from the Internet <URL:https://incidecoder.com/products/revolution-good-b>. [cited by applicant]
Laboratoire Nuxe, “24HR Moisturizing Anti-Fatigue Concentrate,” Record ID: 1287042, Mar. 2010, 5 pages. [cited by applicant]
Nurlaily, A. et al. “Comparative Antioxidant and Anti-Inflammatory Activity of Different Extracts of [cited by applicant]
Waterman, K. C. et al. “Accelerated Aging: Prediction of Chemical Stability of Pharmaceuticals.” International Journal of Pharmaceutics, vol. 293, Nos. 1-2, Apr. 11, 2005, pp. 101-125. [cited by applicant]